Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H2 2016
- Pages: 421
- Published: November 2016
- Report Code: GMDHC8677IDB
Global Markets Direct’s, ‘Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H2 2016’, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
The report reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Methicillin-Resistant Staphylococcus aureus (MRSA) Infections therapeutics and enlists all their major and minor projects
The report assesses Methicillin-Resistant Staphylococcus aureus (MRSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Absynth Biologics Limited
Actelion Ltd
Adenium Biotech ApS
AIMM Therapeutics B.V.
Alchemia Limited
Allergan Plc
AlphaMab Co., Ltd
Alvogen Korea Co., Ltd.
AmpliPhi Biosciences Corporation
AnGes MG, Inc.
Antibiotx ApS
Aphios Corporation
Aridis Pharmaceuticals LLC
Arsanis, Inc.
AstraZeneca Plc
Atriva Therapeutics GmbH
Bavarian Nordic A/S
Bharat Biotech International Limited
C3 Jian, Inc
Cellceutix Corporation
Cempra Inc
Citius Pharmaceuticals, Inc.
Common Pharma Inc
ContraFect Corporation
Crestone, Inc.
Critical Outcome Technologies Inc
CrystalGenomics, Inc.
CSA Biotechnologies LLC
Debiopharm International SA
Dermala Inc
DesignMedix, Inc.
Destiny Pharma Limited
Dong-A Socio Holdings Co. Ltd.
e-Therapeutics Plc
Emergent BioSolutions Inc.
Ensol Biosciences Inc.
Excelimmune, Inc.
Galapagos NV
GangaGen Inc.
Gero Corp
Helix BioMedix, Inc.
Hsiri Therapeutics LLC
Ildong Pharmaceutical Co., Ltd.
Immupharma Plc
iNtRON Biotechnology Inc.
ioGenetics, Inc.
Kyorin Pharmaceutical Co., Ltd.
Lascco SA
LegoChem Biosciences, Inc
Lipocure Ltd.
Madam Therapeutics B.V.
Melinta Therapeutics, Inc
Merck & Co., Inc.
Microbiotix, Inc.
MicuRx Pharmaceuticals, Inc.
MorphoSys AG
Motif Bio Plc
Nabriva Therapeutics AG
Nemus Bioscience, Inc.
Novabiotics Limited
NovaDigm Therapeutics, Inc.
NovoBiotic Pharmaceuticals, LLC
Omnia Molecular Ltd.
Oragenics, Inc.
Pfizer Inc.
Phico Therapeutics Limited
Procarta Biosystems Limited
Prommune, Inc.
Recce Pty Ltd
Redx Pharma Plc
Sarepta Therapeutics, Inc.
Savara Inc.
Sealife PHARMA GMBH
Sentinella Pharmaceuticals, Inc.
Sequoia Sciences Inc
Soligenix, Inc.
Sorrento Therapeutics Inc
Taejoon Pharm Co., Ltd.
TAXIS Pharmaceuticals, Inc.
Telephus Medical LLC
Tetraphase Pharmaceuticals Inc.
TGV-Laboratories
Theravance Biopharma Inc
Trellis Bioscience, Inc.
Valevia UK Limited
VLP Biotech, Inc.
Wintermute Biomedical LLC
Wockhardt Limited
XBiotech Inc
Yungjin Pharm. Co., Ltd.
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.